AR030551A1 - Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante - Google Patents
Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultanteInfo
- Publication number
- AR030551A1 AR030551A1 ARP010100761A ARP010100761A AR030551A1 AR 030551 A1 AR030551 A1 AR 030551A1 AR P010100761 A ARP010100761 A AR P010100761A AR P010100761 A ARP010100761 A AR P010100761A AR 030551 A1 AR030551 A1 AR 030551A1
- Authority
- AR
- Argentina
- Prior art keywords
- nefiracetam
- composition
- neurodegeneration
- manufacture
- processing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Uso de N-(-2,6-dimetilfenil)-2-(2-oxo-1-pirrolidinil) acetamida (nefiracetam) para la preparacion de medicamentos, particularmente de composiciones farmacéuticas que lo contienen como ingrediente activo, para el tratamiento de la neurodegeneracion, en particular en pacientes humanos después de un ataque cerebral. La administracion temprana de nefiracetam en dichas composiciones farmacéuticas después de un ataque cerebral permite una mejora en las Actividades del Diario Vivir y en la recuperacion, o al menos en la mejora de la recuperacion de pacientes después del ataque cerebral. Composicion farmacéutica que comprende una cantidad farmacologicamente efectiva de nefiracetam, como ingrediente activo y un vehículo farmacéuticamente aceptable. La composicion se presenta en una dosis unitaria de administracion oral, particularmente que contiene entre 50 y 1200 mg de nefiracetam.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51195200A | 2000-02-23 | 2000-02-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR030551A1 true AR030551A1 (es) | 2003-08-27 |
Family
ID=24037094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010100761A AR030551A1 (es) | 2000-02-23 | 2001-02-21 | Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6423739B1 (es) |
| EP (1) | EP1171123B1 (es) |
| JP (1) | JP2003523385A (es) |
| KR (1) | KR20010110798A (es) |
| CN (1) | CN1362877A (es) |
| AR (1) | AR030551A1 (es) |
| AT (1) | ATE336246T1 (es) |
| AU (1) | AU784418B2 (es) |
| BR (1) | BR0104586A (es) |
| CA (1) | CA2368352C (es) |
| DE (1) | DE60122252T2 (es) |
| DK (1) | DK1171123T3 (es) |
| ES (1) | ES2270981T3 (es) |
| HK (1) | HK1047038A1 (es) |
| ID (1) | ID30377A (es) |
| IL (1) | IL145799A (es) |
| MX (1) | MXPA01010749A (es) |
| NO (1) | NO321911B1 (es) |
| TW (1) | TWI289060B (es) |
| WO (1) | WO2001062246A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077709A1 (en) * | 1999-05-31 | 2004-04-22 | Daiichi Pharmaceutical Co., Ltd. | Neuronal death inhibitors |
| MXPA03005889A (es) * | 2000-12-28 | 2005-02-14 | Daiichi Seiyaku Co | Agente para tratamiento terapeutico y profilactico del dolor neuropatico. |
| WO2003018005A1 (en) * | 2001-08-22 | 2003-03-06 | Daiichi Pharmaceutical Co., Ltd. | use of nefiracetam for treating neurodegeneration |
| RU2205631C1 (ru) * | 2002-06-19 | 2003-06-10 | Закрытое акционерное общество "Брынцалов-А" | Ноотропное средство "ноотобрил" в форме таблеток |
| US20060241144A1 (en) * | 2005-04-20 | 2006-10-26 | Albert Cha | Method for treating apathy syndrome |
| NO2490685T3 (es) | 2009-10-22 | 2018-05-12 | ||
| RU2480214C1 (ru) * | 2011-09-22 | 2013-04-27 | Валентина Ивановна Ахапкина | Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2469995A (en) * | 1946-07-23 | 1949-05-10 | Schaul Martin Carl | Process for the production of food preparations from potatoes and similar farinaceoustubers |
| US3031314A (en) * | 1960-03-16 | 1962-04-24 | Carl E Hendel | Preparation of dehydrated potatoes |
| US3260607A (en) * | 1961-02-07 | 1966-07-12 | Canadian Patents Dev | Preparation of dehydrated cooked mashed potato |
| US3968265A (en) * | 1973-02-01 | 1976-07-06 | American Potato Company | Freeze-thaw stable, french fry potato product and process for producing the same |
| DE2924011C2 (de) | 1979-06-13 | 1982-04-08 | A. Nattermann & Cie GmbH, 5000 Köln | Pyrrolidin-(2)-on-(1)-ylessigsäure-2,6,-dimethylanilid, Verfahren zur Herstellung und Arzneimittel, welche diese Verbindung enthalten |
| DE2923975A1 (de) | 1979-06-13 | 1980-12-18 | Nattermann A & Cie | Pyrrolidinone, verfahren zu deren herstellung und diese enthaltende arzneimittel |
| IT1141287B (it) | 1979-06-13 | 1986-10-01 | Nattermann A & Cie | Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono |
| CZ281170B6 (cs) | 1991-05-02 | 1996-07-17 | Daiichi Pharmaceutical Co., Ltd | Léčivo pro léčení demence |
| US5525058A (en) | 1992-03-27 | 1996-06-11 | American Dental Technologies, Inc. | Dental treatment system |
| KR100232929B1 (ko) | 1995-07-10 | 1999-12-01 | 히로지 코데라 | 가공 선재의 접속 장치 |
| US6107330A (en) | 1995-08-07 | 2000-08-22 | Daiichi Pharmaceutical Co., Ltd. | Inhibitor for narcotic analgesic dependence/resistance acquisition |
| JP2002241272A (ja) | 1996-07-18 | 2002-08-28 | Mitsubishi Pharma Corp | 医薬処方組成物 |
| ATE226017T1 (de) | 1996-07-30 | 2002-11-15 | Ecolab Gmbh & Co Ohg | Filmbildendes mittel zum schutz vor infektionen |
| KR20000048847A (ko) | 1996-10-01 | 2000-07-25 | 스즈키 다다시 | 미토콘드리아 막 안정화제 |
| US6211701B1 (en) | 1996-12-16 | 2001-04-03 | Rose Research, Llc | Low power line switching circuit, device and method |
| IT1293533B1 (it) | 1997-07-14 | 1999-03-01 | Angeletti P Ist Richerche Bio | Metodo per la selezione di molecole in grado di mimare, inibire o potenziare gli effetti della interazione tra leptina e cellule che |
| DE69823851D1 (de) | 1997-07-15 | 2004-06-17 | Daiichi Seiyaku Co | Nefiracetam zur prophylaxe und behandlung von propofol verursachtem gedächtnisschwund |
| JPH1180027A (ja) | 1997-09-12 | 1999-03-23 | Dai Ichi Seiyaku Co Ltd | 向知性薬 |
| TW544311B (en) | 1998-08-06 | 2003-08-01 | Daiichi Seiyaku Co | Therapeutic or preventive agent for intractable epilepsies |
| AU5102900A (en) | 1999-05-31 | 2000-12-18 | Daiichi Pharmaceutical Co., Ltd. | Neuronal death inhibitors |
-
2001
- 2001-02-16 US US09/784,048 patent/US6423739B1/en not_active Expired - Fee Related
- 2001-02-21 AR ARP010100761A patent/AR030551A1/es unknown
- 2001-02-23 CA CA002368352A patent/CA2368352C/en not_active Expired - Fee Related
- 2001-02-23 KR KR1020017013542A patent/KR20010110798A/ko not_active Ceased
- 2001-02-23 JP JP2001561312A patent/JP2003523385A/ja active Pending
- 2001-02-23 AU AU34145/01A patent/AU784418B2/en not_active Ceased
- 2001-02-23 HK HK02108589.8A patent/HK1047038A1/zh unknown
- 2001-02-23 IL IL145799A patent/IL145799A/en not_active IP Right Cessation
- 2001-02-23 CN CN01800298A patent/CN1362877A/zh active Pending
- 2001-02-23 DE DE60122252T patent/DE60122252T2/de not_active Expired - Lifetime
- 2001-02-23 TW TW090104150A patent/TWI289060B/zh not_active IP Right Cessation
- 2001-02-23 ES ES01906242T patent/ES2270981T3/es not_active Expired - Lifetime
- 2001-02-23 EP EP01906242A patent/EP1171123B1/en not_active Expired - Lifetime
- 2001-02-23 ID IDW00200102283A patent/ID30377A/id unknown
- 2001-02-23 DK DK01906242T patent/DK1171123T3/da active
- 2001-02-23 AT AT01906242T patent/ATE336246T1/de not_active IP Right Cessation
- 2001-02-23 MX MXPA01010749A patent/MXPA01010749A/es active IP Right Grant
- 2001-02-23 BR BR0104586-5A patent/BR0104586A/pt not_active Application Discontinuation
- 2001-02-23 WO PCT/JP2001/001342 patent/WO2001062246A1/en not_active Ceased
- 2001-07-17 US US09/906,077 patent/US6399650B2/en not_active Expired - Fee Related
- 2001-10-22 NO NO20015162A patent/NO321911B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010110798A (ko) | 2001-12-13 |
| EP1171123B1 (en) | 2006-08-16 |
| CA2368352A1 (en) | 2001-08-30 |
| NO20015162D0 (no) | 2001-10-22 |
| TWI289060B (en) | 2007-11-01 |
| ES2270981T3 (es) | 2007-04-16 |
| US6423739B1 (en) | 2002-07-23 |
| US20020055534A1 (en) | 2002-05-09 |
| ATE336246T1 (de) | 2006-09-15 |
| NO321911B1 (no) | 2006-07-17 |
| ID30377A (id) | 2001-11-29 |
| DE60122252D1 (de) | 2006-09-28 |
| JP2003523385A (ja) | 2003-08-05 |
| US6399650B2 (en) | 2002-06-04 |
| IL145799A0 (en) | 2002-07-25 |
| CN1362877A (zh) | 2002-08-07 |
| WO2001062246A1 (en) | 2001-08-30 |
| NO20015162L (no) | 2001-12-21 |
| IL145799A (en) | 2006-10-31 |
| MXPA01010749A (es) | 2002-08-20 |
| BR0104586A (pt) | 2002-01-08 |
| HK1047038A1 (zh) | 2003-02-07 |
| US20010051653A1 (en) | 2001-12-13 |
| AU3414501A (en) | 2001-09-03 |
| EP1171123A1 (en) | 2002-01-16 |
| AU784418B2 (en) | 2006-03-30 |
| CA2368352C (en) | 2009-11-10 |
| DE60122252T2 (de) | 2007-07-05 |
| DK1171123T3 (da) | 2006-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| AR020001A1 (es) | COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO | |
| WO2005046640A3 (en) | Multi-site drug delivery platform | |
| AR035927A1 (es) | Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr | |
| BRPI0108435B8 (pt) | formulação e uso de entecavir de baixa dose | |
| DE602004032149D1 (de) | Oros-push-stick für die kontrollierte abgabe von wirkstoffen | |
| IS7006A (is) | Tvívetnis 3-piperidínóprópíófenon og lyf sem innihalda téð efnasambönd | |
| MX2007015480A (es) | Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada. | |
| RU2004135563A (ru) | Лекарственное средство для лечения повышенной активности мочевого пузыря | |
| AR045783A1 (es) | Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide | |
| AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
| ES2175663T3 (es) | Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis. | |
| ATE262893T1 (de) | Darreichungsformen zur behandlung von oralen mykosen | |
| RU2002122084A (ru) | Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных растройств | |
| AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
| WO2006072940A3 (en) | Controlled long acting release pharmaceutical preparation for use in the oral cavity | |
| AR030551A1 (es) | Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante | |
| CA2504872A1 (en) | Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections | |
| RU2005105302A (ru) | Композиция бицифадина | |
| BR9913982A (pt) | Derivado de piridil-4h-1,2,4-oxadiazina opticamente ativo e seu uso no tratamento de doenças vasculares | |
| AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
| UY26595A1 (es) | Formulaciones de entecavir de dosis bajas y uso | |
| CA2474430A1 (en) | A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction | |
| CA2727722A1 (en) | Use of dihydroimidazolones for the treatment of anxiety in dogs | |
| CA2457982A1 (en) | Use of nefiracetam for treating neurodegeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |